NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ACULAR (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. First approved in 1992.
Drug data last refreshed 3h ago · AI intelligence enriched 6h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACULAR (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) administered as an ophthalmic solution for topical eye use. It works by inhibiting prostaglandin biosynthesis to provide analgesic, anti-inflammatory, and anti-pyretic effects in ocular tissues. It is indicated for relief of ocular itching due to seasonal allergies and postoperative ocular pain.
$0.075BPart D
LOE ApproachingDeclining
As LOE approaches, brand teams will shift from growth maintenance to lifecycle extension strategies and generic transition planning.
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Started Jan 2027
321 enrolled
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Study of CU06-1004 in Patients With Daibetic Macular Edema
Started Dec 2026
156 enrolled
DMEDiabetic Macular EdemaDiabetic Macular Edema (DME)
A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
Started Oct 2026
9 enrolled
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
Started Oct 2026
400 enrolled
Wet Age-related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
Started Oct 2026
450 enrolled
Diabetic Macular Edema (DME)
Worked on ACULAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.